

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1. (Cancelled).

Claim 2. (Currently amended) The use method according to claim 4 21, characterised in that wherein said composition is consists of a nutritional composition suitable for oral administration.

Claim 3. (Currently amended) The use method according to claim 2, characterised in that wherein said nutritional composition is designed to stimulate bone formation in young individuals in the growth phase.

Claim 4. (Currently amended) The use method according to claim 2, characterised in that wherein said nutritional composition is designed to prevent the bone loss which occurs with ageing.

Claim 5. (Currently amended) The use method according to claim 2, characterised in that wherein said nutritional composition is designed to prevent or treat disorders linked to an imbalance in the relationship between bone formation and bone resorption.

Claim 6. (Currently amended) The use method according to Claim 2, characterised in that wherein said nutritional composition is designed to treat a bone deficit resulting from a fracture.

Claim 7. (Currently amended) the use according to Claim 6 2, characterised in that wherein said nutritional composition is designed to prevent or treat a disease selected from osteoporosis, Paget's disease, bone loss or osteolysis observed close to a prosthesis, metastatic bone diseases, hypercalcemia due to a cancer, multiple myelomas, periodontal

diseases or osteoarthritis.

Claim 8. (Currently amended) The ~~use~~ method according to claim 2 ~~one of the Claims 2 to 7, characterised in that~~ wherein said nutritional composition is available in the form of drinks, including juices, ~~preferably fruit juices~~, yoghurts, ice creams, cheeses, baked products such as bread, biscuits and cakes, dairy products, desserts, confectionery products, cereal bars, breakfast cereals, food seasoning products, fruit salads or stewed fruit.

Claim 9 (Currently amended) The ~~use~~ method according to claim 2 ~~one of the Claims 2 to 7, characterised in that~~ wherein said nutritional composition is available in the form of a product designed for animal feed, in a wet, semi-wet or dry form.

Claim 10 (Currently amended) The ~~use~~ method according to claim 2 ~~one of the Claims 2 to 9, characterised in that~~ wherein the compound hesperidin or one of its derivatives is available in the form of an extraction product obtained from the peel or the pulp of a citrus fruit.

Claim 11 (Currently amended) The ~~use~~ method according to claim 2 ~~one of the Claims 2 to 10, characterised in that~~ wherein said nutritional composition compound is adapted for oral administration of a daily quantity included between 0.01 and 500 mg of the compound hesperidin or of one of its derivatives.

Claim 12 (Canceled)

Claim 13 (Currently amended) The ~~use~~ method according to claim 21 1, ~~characterised in that~~ wherein said composition is consists of a human pharmaceutical or veterinary composition.

Claim 14 (Currently amended) The ~~use~~ method according to claim 13, ~~characterised in that~~ wherein said pharmaceutical composition is designed to stimulate bone formation in the young individual in the growth phase.

Claim 15 (Currently amended) The use method according to claim 13, characterised in that wherein said pharmaceutical composition is designed to prevent the bone loss which occurs in the course of ageing.

Claim 16 (Currently amended) The use method according to claim 13, characterised in that wherein said pharmaceutical composition is designed to prevent or treat a disease linked to an imbalance in the relationship between bone formation and bone resorption.

Claim 17 (Currently amended) The use method according to claim 13, characterised in that wherein said pharmaceutical composition is designed to treat a bone deficit resulting from a fracture.

Claim 18 (Currently amended) The use method according to claim 13, characterised in that wherein said composition is designed to prevent or treat a disease selected from osteoporosis, Paget's disease, bone loss or the osteolysis observed close to a prosthesis, metastatic bone diseases, the hypercalcemia due to a cancer, multiple myelomas, periodontal diseases or osteoarthritis.

Claim 19 (Currently amended) The use method according to claim 13 ~~one of the Claims 13 to 18~~, characterised in that wherein said pharmaceutical composition is available in a form for oral, parenteral or intravenous administration.

Claim 20 (Currently amended): The use method according to claim 13 ~~one of the Claims 13 to 18~~, characterised in that wherein the pharmaceutical composition is suitable for an oral administration of a daily quantity included between 0.01 and 500 mg of the compound hesperidin or of one of its derivatives.

Claim 21 (New) A method for stimulating bone formation and/or inhibiting bone resorption in man or animals comprising a step of administering to a subject in need thereof, an

effective amount of a composition containing hesperidin or a derivative thereof selected from the group consisting of hesperitin, alpha-glucosyl-hesperidin, methyl hesperidin, a conjugate of hesperitin and sulphate and a conjugate of hesperitin and glucuronide.

Claim 22 (New) The method according to claim 8, wherein the nutritional composition is available in the form a fruit juice.